SS
TRIB

Simplicity Solutions’s Trinity Biotech TRIB Stock Holding History

Simplicity Solutions’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,471
Closed -$103K – 438
2017
Q1 		$103K Buy
+3,471
New +$109K 0.02% 392

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Simplicity Solutions's TRIB Position: Q2 2017 in Review

Simplicity Solutions sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 3,471 shares — an estimated $103K sold.

Simplicity Solutions first reported a position in TRIB in Q1 2017 and held it in 1 quarter. The position peaked at $103K in Q1 2017. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • Simplicity Solutions reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • Simplicity Solutions sold 3,471 Trinity Biotech shares in Q2 2017, an estimated $103K.
  • Simplicity Solutions first reported a position in Trinity Biotech in Q1 2017 and held it in 1 quarter.
  • Simplicity Solutions's Trinity Biotech position peaked at $103K in Q1 2017.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Simplicity Solutions's 13F filing for Q2 2017, filed 9 Aug 2017.